Award Data

While CAR-T therapies have advanced in the clinic, there are still two specific issues using these breakthrough therapies for blood cancers: Durable responses in patients are only at 30-50% and Cytokine Release Syndrome occurs in 60-90% of treated patients. These limitations, for a drug that costs as much as $500,000, may cost an additional $250,000+ for treating adverse events leading to caution ...

Biomason’s prototype MEDUSA dust abatement system provides a superior performing, logistically lean, and environmentally friendly solution for rapid dust suppression for VTOL operations in austere, forward operating positions. Moreover, base MEDUSA systems and processes may be adapted for utilization in multiple industrial sectors and serve several other key military and civilian use-cases - fro ...

This ARPA-H SBIR Phase II project aims to develop an 'autonomous' minimally invasive surgery approach, enhancing outcomes in procedures like laparoscopic cholecystectomy through advanced robotic tools and a 'smart' vision framework. The research team will explore whether the novel robotic platform can elevate the safety and efficiency of gallbladder removal surgery by integrating supervised autono ...

The project aims to advance the development of BL-760, a near-infrared contrast agent designed for clear intraoperative identification of bile ducts. This novel dye addresses the significant medical issue of bile duct injury during hepatobiliary surgeries (e.g., cholecystectomy, hepatectomy), impacting over 1 million patients annually. The project plans to produce BL-760 with high quality standard ...

Current treatments for asthma, while reducing exacerbations in a subset of patients by focusing on airway inflammation, do not eliminate them. Asthma exacerbations are a significant cause of morbidity and mortality in asthma as they can lead to airway injury, lung function decline and death. Exacerbations in more severe asthmatics are of particular concern, as health care costs and lost productivi ...

In Phase I, Kutta defined and detailed its vision for a subterranean wireless communication system that gives America’s soldiers the ability to communicate more effectively and efficiently than ever before in underground caves and urban tunnels. During Phase I, Kutta exceeded the Army’s Phase I distance transmission requirements by nearly four-fold feet by demonstrating the ability to send voi ...

In Phase I, Kutta Consulting defined and detailed its vision for a Dismounted Associate (DA) that gives America's soldiers over-the-hill battlefield intelligence. Kutta, however, did not act alone. AATD, Boeing Phantom Works, General Dynamics, Advanced Ceramics Research, Neural Robotics Incorporated, 21st Century Systems, and numerous user groups contributed significant concepts, subject matter ex ...

In the proposed effort, we will establish all of the basic components working together in a laboratory environment, in order to demonstrate our impulsive energy deposition technology for high-speed flight. We will also identify DoD systems, applications, and requirements, that will most benefit from our technology, including the critical next steps to advance the technology to flight tests. Approv ...

DESCRIPTION (provided by applicant): One in every four deaths in the US is due to cancer. The overall cancer drug market exceeds $2 billion in the USA. There is significant need to identify novel, effective, small molecule-based cancer therapies. This proposal seeks to undertake further clinical development of a novel targeted agent, PX-12. ProIX Pharmaceuticals has demonstrated there is strong ev ...

Summary: This Phase IIb grant application describes a plan for demonstrating significant improvement of identifying ASD subjects at a very young age and facilitating diagnostic assessments for autism earlier via a proven telehealth service. The plan includes partnering with a private company (CHADIS) that has a substantial client base of referring pediatricians already using their technology to sc ...